20140616-招商证券-2H14_China_Healthcare_Equity_Strategy_Crowded_trade_in_reverse__Selective_BOD_60页_4mb

2H14 China Healthcare Equity Strategy Summary

Core Content

This document outlines the equity strategy for the China healthcare sector in the second half of 2014, focusing on investment opportunities and key factors influencing the market. It emphasizes the importance of the tender process, M&A activity, and R&D pipelines in driving growth. The strategy suggests a "Buy-on-Dip" approach, targeting companies that demonstrate strong fundamentals and growth potential.

Main Points

Sector Overview

• Outperformance: The China healthcare sector outperformed the Hang Seng Index (HSI) in 2014, driven by new IPOs and sector-specific catalysts.
• Sector Growth: The healthcare sector is expected to grow at 2x the rate of China's GDP, supported by aging demographics, increased public healthcare spending, and rising disposable incomes.
• Key Catalysts: Tender progress, NRDL updates, policy announcements, M&A deal announcements, and R&D milestones are key drivers for the sector.
• Downside Risks: Delays in tender execution, policy changes, anti-corruption campaigns, pipeline failures, and rising raw material costs are potential risks.
• Multiple Expansion: The sector is undergoing a re-rating trend, with investors focusing on long-term value creation through R&D, product portfolio, and market positioning.

Equity Strategy

• Investment Focus: The strategy favors companies with strong R&D capabilities, value chain integration, and emerging medical service themes.
• Stock Picks: The following companies are recommended as "Buy" opportunities:
  • Sihuan (460.HK): 20% upside
  • Dawnrays (2348.HK): 41% upside
  • Essex (1061.HK): 46% upside
  • Phoenix (1515.HK): 58% upside
  • CSPC (1093.HK): 31% upside
  • Sinopharm (1099.HK): 15% upside
  • iKang (KANG.US): 21% upside
  • Sino Biopharma (1177.HK): 3% upside
• Neutral on Shineway (2877.HK): Due to limited upside and a small negative gap between target price and current price.

Key Investment Drivers

• Tender Progress: Expected to drive growth in 2014-2015, with exclusivity still being a key factor.
• M&A Activity: Seen as a critical business strategy, with a focus on quality targets and synergy integration.
• R&D Pipeline: Companies with strong R&D capabilities and a diverse pipeline of innovative and generic drugs are preferred.
• Market Expansion: Both domestic and international expansion are emphasized, especially in the OTC and medical services sectors.

Key Risks

• Policy Risks: Ongoing anti-corruption campaigns and government price controls.
• Tender Delays: Structural issues and local conflicts may affect tender execution.
• M&A Execution: Success of M&A deals depends on effective integration and synergy.
• Pipeline Failure: Potential setbacks in drug development could impact growth.

Key Information

Company Highlights

Financial Highlights

Investment Strategy

• Buy-on-Dip: The strategy recommends buying stocks after a 25% pullback.
• Preferred Companies:
  1. R&D and scale leaders
  2. Value-chain climbers
  3. Companies with emerging themes in medical services
• Avoid:
  • Sub-scaled players
  • Commodity producers
  • Tender dropouts

Conclusion

The China healthcare sector presents significant growth opportunities, driven by tender progress, M&A, and R&D pipelines. The strategy focuses on companies with strong fundamentals, long-term value creation potential, and a competitive edge in the market. Investors are advised to look for "Buy-on-Dip" opportunities and avoid companies with limited growth prospects or high downside risks.